Efficacy of HER2-Targeted Intraperitoneal<sup>225</sup>Ac α-Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis-Reference-Cited by-同舟云学术

Efficacy of HER2-Targeted Intraperitoneal²²⁵Ac α-Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis

Published:2023-06-22 Issue:9 Volume:64 Page:1439-1445
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Chung Sebastian K.,Vargas Daniela Burnes,Chandler Christopher S.,Katugampola Sumudu,Veach Darren R.,McDevitt Michael R.,Seo Shin H.,Vaughn Brett A.,Rinne Sara S.,Punzalan Blesida,Patel Mitesh,Xu Hong,Guo Hong-Fen,Zanzonico Pat B.,Monette Sébastien,Yang Guangbin,Ouerfelli Ouathek,Nash Garrett M.,Cercek Andrea,Fung Edward K.,Howell Roger W.,Larson Steven M.,Cheal Sarah M.,Cheung Nai-Kong V.

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference35 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Staging classification for cancer of the ovary, fallopian tube, and peritoneum

3. Survival time, causes of death, and tumor/treatment-related morbidity in 100 women with ovarian cancer

4. Palliative radiation therapy for metastatic, persistent, or recurrent epithelial ovarian cancer: efficacy in the era of modern technology and targeted agents;Butala;Adv Radiat Oncol.,2020

5. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trends in cancer imaging;Trends in Cancer;2024-09

2. Targeting Cancer Stem Cells with Radioimmunotherapy: The Case of the Ovarian Cancer Stemness-Associated Biomarker L1CAM;International Journal of Translational Medicine;2024-07-18

3. Advances in Radioligand Theranostics in Oncology;Molecular Diagnosis & Therapy;2024-03-31

4. The present and future of bispecific antibodies for cancer therapy;Nature Reviews Drug Discovery;2024-03-06

5. Pb-214/Bi-214-TCMC-Trastuzumab inhibited growth of ovarian cancer in preclinical mouse models;Frontiers in Chemistry;2024-01-25